Cisplatin and cetuximab are effective chemotherapies for head and neck cancers, and both drugs can sensitize tumors to radiation therapy. Bevacizumab is a newer drug which is approved for treating advanced colorectal, lung, breast, and brain cancers. It works by interfering with the growth of blood vessels that support tumor growth and survival.
Intensity-modulated radiation therapy (IMRT) is a targeted form of radiation therapy that is the standard of care for patients with head and neck cancers. The purpose of this study is to determine the effectiveness of combination treatment with bevacizumab, cisplatin, cetuximab, and IMRT in patients with stage III/IV head and neck cancer. Patients will be followed for two years to see if they are cancer-free during this time.